Skip to content
Original
news.google.com· FierceBiotech·· 17 hours agoScore44

ESMO: Roche touts ‘convincing’ phase 3 KRAS data after win over rivals - Fierce Biotech

In brief

Roche presented phase 3 KRAS data at ESMO and called the results 'convincing,' after coming out ahead of rivals. The specific drug, trial name and key statistics were not disclosed in the available material.

Source: news.google.com · news.google.com

#Clinical readout#Conference#Oncology#Roche
CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.